Allogene Therapeutics (ALLO) said Monday that the US Food and Drug Administration granted three fast track designations for ALLO-329, which the company is developing to treat autoimmune diseases.
The designations cover the treatment of adult patients with active refractory moderate-to-severe systemic lupus erythematous, active severe or refractory idiopathic inflammatory myopathy, and active refractory diffuse systemic sclerosis (Scleroderma), according to the company.
Allogene said FDA's fast track designation is intended to expedite the development and review of therapies that address serious or life-threatening conditions and demonstrate the potential to meet unmet medical needs.
The company said it plans to start a phase 1 trial of ALLO-329 in the diseases covered by the three fast track designations in mid-2025, with proof-of-concept from the trial expected by the end of the year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。